Amend CSHB 1924 by adding the following appropriately 
numbered SECTION to the bill and renumbering subsequent SECTIONS of 
the bill accordingly:
	SECTION ___.  Section 556.053, Occupations Code, is amended 
to read as follows:
	Sec. 556.053.  EXTENT OF INSPECTION; CONFIDENTIALITY.  
(a)  Except as otherwise provided in an inspection warrant, the 
person authorized to represent the board may:
		(1)  inspect and copy documents, including records or 
reports, required to be kept or made under this subtitle, Chapter 
481 or 483, Health and Safety Code, or the Comprehensive Drug Abuse 
Prevention and Control Act of 1970 (21 U.S.C. Section 801 et seq.) 
or rules adopted under one of those laws;
		(2)  inspect, within reasonable limits and in a 
reasonable manner, a facility's storage, equipment, security, 
prescription drugs or devices, components used in compounding, 
finished and unfinished products, or records; or
		(3)  perform an inventory of any stock of prescription 
drugs or devices, components used in compounding, or finished and 
unfinished products in a facility and obtain samples of those 
substances.
	(b)  Reports, records, formulas, and test results of samples 
of products compounded by pharmacies obtained by the board may be 
provided to the pharmacy that compounded the product but otherwise 
are confidential and do not constitute public information for 
purposes of Chapter 552, Government Code.  The board may create, 
use, or disclose statistical information from the test results of 
samples of compounded products.
	(c)  The board may disclose information confidential under 
Subsection (b):
		(1)  in a disciplinary hearing before the board or in a 
subsequent trial or appeal of a board action or order;
		(2)  to a pharmacist licensing or disciplinary 
authority of another jurisdiction; or
		(3)  under a court order.                                              
	(d)  The board shall require a pharmacy to recall a 
compounded product and may release the results of the tests of the 
samples of the compounded product if the board determines that:
		(1)  the test results indicate a patient safety problem 
that may involve potential harm to a patient; and
		(2)  the release of the test results is necessary to 
protect the public.
	(e)  The board shall release the test results described by 
Subsection (d) if a pharmacy is unable to or does not recall the 
compounded product within 48 hours after the board's request under 
that subsection.